503a compounding pharmacy semaglutide Webster BreezeMeds Reviewed: 2026 Consumer Report

Tier Product description Product Specifications Active Compound: Retatrutide peptide Strength: 30mg per vial Form: Lyophilized powder Reconstitution Required: Yes, according to a validated laboratory protocol Manufacturer, as listed: Novera Compounds Country of Origin, as listed: United States Brand: Novera Intended Use: Laboratory and in vitro research only Package Content: 1 x 30mg vial Weight: 7 grams Dimensions: Width: 20mm | Height: 40mm | Length: 20mm Human-Use Status: Not approved for human use, clinical application, injection, or consumption What Is Retatrutide 30mg

It is administered as a once-weekly injection and is frequently compared to other GLP-1 medications such as Ozempic and Mounjaro, which serve similar therapeutic purposes but differ in dosing and reported side effect profiles

The FDA allows compounding medications under sections 503A and 503B in case of drug shortages

Under 503A, a state-licensed compounding pharmacy can prepare patient-specific semaglutide or tirzepatide formulations when a prescriber documents a clinically significant difference from the commercial product, for example an intolerance-driven microdose titration or a preservative-free formulation

A: Most don't

Contamination is the silent killer of good data